Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$0.11 - $5.46 $0 - $5
1 Added 0.0%
207,025 $22,000
Q4 2021

Feb 11, 2022

SELL
$0.6 - $1.11 $16,211 - $29,991
-27,019 Reduced 11.54%
207,024 $127,000
Q3 2021

Nov 10, 2021

SELL
$1.01 - $1.82 $4,020 - $7,245
-3,981 Reduced 1.67%
234,043 $239,000
Q2 2021

Aug 04, 2021

BUY
$1.39 - $2.21 $5,560 - $8,840
4,000 Added 1.71%
238,024 $436,000
Q4 2020

Jan 29, 2021

SELL
$0.94 - $1.89 $7,520 - $15,120
-8,000 Reduced 3.31%
234,024 $293,000
Q3 2020

Nov 05, 2020

BUY
$1.5 - $9.38 $43,050 - $269,206
28,700 Added 13.45%
242,024 $436,000
Q2 2020

Jul 23, 2020

BUY
$4.79 - $8.39 $991 - $1,736
207 Added 0.1%
213,324 $1.79 Million
Q1 2020

May 05, 2020

BUY
$3.44 - $7.21 $36,484 - $76,469
10,606 Added 5.24%
213,117 $1.12 Million
Q4 2019

Jan 30, 2020

BUY
$4.29 - $5.64 $15,117 - $19,875
3,524 Added 1.77%
202,511 $1.11 Million
Q3 2019

Nov 01, 2019

SELL
$4.87 - $7.08 $540 - $785
-111 Reduced 0.06%
198,987 $969,000
Q2 2019

Jul 26, 2019

SELL
$6.6 - $7.8 $255,657 - $302,140
-38,736 Reduced 16.29%
199,098 $1.38 Million
Q1 2019

Apr 24, 2019

BUY
$5.76 - $8.95 $220,394 - $342,453
38,263 Added 19.17%
237,834 $1.65 Million
Q4 2018

Feb 01, 2019

SELL
$5.26 - $7.97 $12,003 - $18,187
-2,282 Reduced 1.13%
199,571 $1.17 Million
Q3 2018

Oct 25, 2018

BUY
$4.65 - $7.95 $9,448 - $16,154
2,032 Added 1.02%
201,853 $1.52 Million
Q2 2018

Jul 20, 2018

BUY
$5.05 - $6.8 $5,989 - $8,064
1,186 Added 0.6%
199,821 $1.01 Million
Q1 2018

Apr 18, 2018

BUY
$5.6 - $9.25 $109,676 - $181,161
19,585 Added 10.94%
198,635 $1.21 Million
Q4 2017

Jan 17, 2018

BUY
$6.6 - $7.78 $32,194 - $37,950
4,878 Added 2.8%
179,050 $1.27 Million
Q3 2017

Oct 17, 2017

BUY
$5.75 - $7.75 $1 Million - $1.35 Million
174,172
174,172 $1.25 Million

Others Institutions Holding CRBP

About Corbus Pharmaceuticals Holdings, Inc.


  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $853M
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.